弥漫性大B细胞淋巴瘤患者核糖体与肌动蛋白网络蛋白表达及免疫化疗耐药
采用蛋白质谱分析97例弥漫性大B细胞淋巴瘤(DLBCL)患者肿瘤组织中整体蛋白表达,其中44例为原发耐药或诊断后1年内复发(REF/REL),53例为诊断后无进展生存超过5年(CURED)。共鉴定2127种蛋白,REF/REL组65种过表达蛋白中46种为核糖体蛋白,而CURED组37种过表达蛋白中仅2种为核糖体蛋白(P=7.6×10⁻¹⁰);CURED组37种过表达蛋白中20种与肌动蛋白调控相关,REF/REL组65种中仅1种(P=1.4×10⁻⁹)。免疫组化显示REF/REL组RPS5和RPL17表达更高,CURED组肌动蛋白网络相关MARCKS样蛋白表达更高。作者认为这些发现提示DLBCL免疫化疗耐药的新机制,但尚需针对单个蛋白及蛋白相互作用的功能研究来评估潜在临床效果。
要点
- REF/REL组65种过表达蛋白中46种为核糖体蛋白,CURED组37种中仅2种(P=7.6×10⁻¹⁰)。
- CURED组37种过表达蛋白中20种与肌动蛋白调控相关,REF/REL组65种中仅1种(P=1.4×10⁻⁹)。
- 免疫组化显示REF/REL组RPS5和RPL17表达更高,CURED组MARCKS样蛋白表达更高。
核心结论
- 作者认为这些发现提示DLBCL免疫化疗耐药的新机制,但尚需针对单个蛋白及蛋白相互作用的功能研究来评估潜在临床效果。
研究设计与样本
- 采用蛋白质谱分析97例DLBCL患者显微切割的福尔马林固定石蜡包埋肿瘤组织:44例原发耐药或诊断后1年内复发(REF/REL),53例诊断后无进展生存超过5年(CURED)。
主要发现
- 共鉴定2127种蛋白,其中442种在所有患者中检出,102种差异表达。
- REF/REL组65种蛋白过表达,其中46种为核糖体蛋白;CURED组37种蛋白过表达,其中2种为核糖体蛋白(P=7.6×10⁻¹⁰)。
- CURED组37种过表达蛋白中20种与肌动蛋白调控相关,REF/REL组65种过表达蛋白中1种与肌动蛋白调控相关(P=1.4×10⁻⁹)。
- 免疫组化显示REF/REL组RPS5和RPL17表达更高,CURED组肌动蛋白网络相关MARCKS样蛋白表达更高。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者指出尚需针对单个蛋白及蛋白相互作用的功能研究来评估潜在临床效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Diffuse large B cell lymphoma (DLBCL) patients with early relapse or refractory disease have a very poor outcome. Immunochemotherapy resistance will probably, also in the era of targeted drugs, remain the major cause of treatment failure. We used proteomic mass spectrometry to analyse the global protein expression of micro-dissected formalin-fixed paraffin-embedded tumour tissues from 97 DLBCL patients: 44 with primary refractory disease or relapse within 1 year from diagnosis (REF/REL), and 53 who were progression-free more than 5 years after diagnosis (CURED). We identified 2127 proteins: 442 were found in all patients and 102 were differentially expressed. Sixty-five proteins were overexpressed in REF/REL patients, of which 46 were ribosomal proteins (RPs) compared with 2 of the 37 overexpressed proteins in CURED patients (P = 7·6 × 10-10 ). Twenty of 37 overexpressed proteins in CURED patients were associated with actin regulation, compared with 1 of 65 in REF/REL patients (P = 1·4 × 10-9 ). Immunohistochemical staining showed higher expression of RPS5 and RPL17 in REF/REL patients while MARCKS-like protein, belonging to the actin network, was more highly expressed in CURED patients. Even though functional studies aimed at individual proteins and protein interactions to evaluate potential clinical effect are needed, our findings suggest new mechanisms behind immunochemotherapy resistance in DLBCL.
引用
- Bram Ednersson S, Stenson M, Stern M, et al. Expression of ribosomal and actin network proteins and immunochemotherapy resistance in diffuse large B cell lymphoma patients. Br J Haematol. 2018. PMID: 29767447. doi:10.1111/bjh.15259
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。